This Article Full Text (PDF) Other Versions of this Article: CVI.00058-08v1 15/8/1145    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Google Scholar Articles by Hui, G. Articles by Hashimoto, C. PubMed PubMed Citation Articles by Hui, G. Articles by Hashimoto, C.

 Previous Article  |  Next Article 

Clin. Vaccine Immunol. doi:10.1128/CVI.00058-08
Copyright (c) 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

The Biological Activities of the Anti-Merozoite Surface Protein-1 Antibodies Induced by Adjuvant-Assisted Immunizations in Different Immune Gene Knock-out Mice

Department of Tropical Medicine and Pharmacology, John A. Burns School of Medicine, University of Hawaii at Manoa

^* To whom correspondence should be addressed. Email: ghui{at}hawaii.edu.

	Abstract

Immunizations with P. falciparum MSP1-42 or MSP1-19 induce antibodies that inhibit parasites in vitro, which correlate with in vivo protective immunity by vaccination. We previously showed that several adjuvant formulations can induce anti-MSP1-19 antibodies in IL-6, ICAM-1, CD80, and CD86 knockout (KO) mice, and at levels similar to that obtained in the normal hosts. Here, we determine whether these immune gene KOs or the immuno-potentiating activities of the adjuvants have a more important influence on the induction of parasite inhibitory anti-MSP1-19 antibodies. Results showed that the biological activities of the anti-MSP1-19 antibodies induced by these adjuvants were not affected by the immune gene knockouts. All adjuvant formulations that induced significant inhibitory antibody responses (i.e. >50% inhibition of parasite growth) contained MPL in emulsion carriers, whereas MPL or emulsion carriers alone were ineffective. The ability to retain vaccine efficacy by the MSP1-19/adjuvant formulations in the altered immunological background is a valuable and significant attribute in light of many instances of skewed immune status in the targeted vaccine populations.